After Hours
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility.
Stocks Info
BEAM belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. The current market capitalization of Beam Therapeutics Inc is $2.40B. A total of 1.84 million shares were traded on the day, compared to an average of 2.63M shares.
In the most recent transaction, FMR LLC sold 48,374 shares of BEAM for 20.50 per share on Jul 30 ’25. After the transaction, the insider now owns 2,073,665 company shares. In a previous transaction on Jul 03 ’25, Simon Amy sold 876 shares at 20.12 per share. BEAM shares that Chief Medical Officer owns now total 64,864.
Among the insiders who sold shares, Simon Amy disposed of 374 shares on Jul 01 ’25 at a per-share price of $16.94. This resulted in the Chief Medical Officer holding 65,740 shares of BEAM after the transaction. In another insider transaction, Bellon Christine sold 5,674 shares at $18.35 per share on Apr 01 ’25. Company shares held by the Chief Legal Officer now total 117,294.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. In terms of 52-week highs and lows, BEAM has a high of $35.25 and a low of $13.52.
As of this writing, BEAM has an earnings estimate of -$1.02 per share for the current quarter. EPS was calculated based on a consensus of 10.0 estimates, with a high estimate of -$0.79 per share and a lower estimate of -$1.16. The company reported an EPS of -$1.17 in the last quarter
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. BEAM’s latest balance sheet shows that the firm has $965.65M in Cash & Short Term Investments as of fiscal 2021. There were $142.35M in debt and $213.44M in liabilities at the time. Its Book Value Per Share was $10.39, while its Total Shareholder’s Equity was $826.74M.
Analysts Opinion
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for BEAM is Buy with a score of 4.56.
